The Potentially Therapeutic Role of EPAC in Curbing the Process of Idiopathic Pulmonary Fibrosis via Differential Cellular Pathways
Xinwei Cao,1 Yajun Li,1 Jianrong Shi,2 Huifang Tang1 1Department of Pharmacology, School of Basic Medical Sciences, Zhejiang University, Hangzhou, 310058, People’s Republic of China; 2Department of Clinical Laboratory, Children’s Hospital, Zhejiang University School of Medicine,...
Enregistré dans:
Auteurs principaux: | Cao X, Li Y, Shi J, Tang H |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ad5d3c3a9d8740859ab52884a897f59a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Arecoline Enhances Phosphodiesterase 4A Activity to Promote Transforming Growth Factor-β-Induced Buccal Mucosal Fibroblast Activation via cAMP-Epac1 Signaling Pathway
par: Bo Zhang, et autres
Publié: (2021) -
Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis
par: Michalski JE, et autres
Publié: (2021) -
Effect of home-based pulmonary rehabilitation on functional capacity in people with idiopathic pulmonary fibrosis—a systematic review protocol
par: Revati Amin, et autres
Publié: (2021) -
Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
par: Henrik Jessen, et autres
Publié: (2021) -
The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
par: Wan-Tong Zhang, et autres
Publié: (2021)